Camrelizumab Plus Carboplatin and Pemetrexed As First-Line Therapy for Advanced Non-Squamous Non-Small-cell Lung Cancer: 5-Year Outcomes of the CameL Randomized Phase 3 Study
Caicun Zhou,Gongyan Chen,Yunchao Huang,Jianying Zhou,LiZhu Lin,Jifeng Feng,Zhehai Wang,Yongqian Shu,Jianhua Shi,Yi Hu,QiMing Wang,Ying Cheng,Fengying Wu,Jianhua Chen,Xiaoyan Lin,Yongsheng Wang,Jianan Huang,Jiuwei Cui,Lejie Cao,Yunpeng Liu,Yiping Zhang,Yueyin Pan,Jun Zhao,LiPing Wang,Jianhua Chang,Qun Chen,Xiubao Ren,Wei Zhang,Yun Fan,Zhiyong He,Jian Fang,Kangsheng Gu,XiaoRong Dong,Faguang Jin,Hongjun Gao,Guangyu An,Cuimin Ding,Xiaodong Jiang,Jianping Xiong,Xiangdong Zhou,Sheng Hu,Ping Lu,Anwen Liu,Shuliang Guo,Jianjin Huang,Chengchu Zhu,Jian Zhao,Beili Gao,Yinglan Chen,Chengping Hu,Jian Zhang,Hongmei Zhang,Hui Zhao,Zhigao Wang,Xinjing Ma,Wei Shi
DOI: https://doi.org/10.1136/jitc-2024-009240
IF: 12.469
2024-01-01
Journal for ImmunoTherapy of Cancer
Abstract:BACKGROUND:CameL phase 3 study demonstrated the superiority of camrelizumab plus chemotherapy over chemotherapy alone for progression-free survival in patients with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations. Here, we present the 5-year outcomes. METHODS:Patients were randomized (1:1) and received 4-6 cycles of camrelizumab plus carboplatin and pemetrexed (n=205) or carboplatin and pemetrexed (n=207) every 3 weeks, followed by maintenance camrelizumab plus pemetrexed or pemetrexed only. Crossover from chemotherapy group to camrelizumab monotherapy was permitted after disease progression. RESULTS:Median time from randomization to data cut-off was 65.2 months (range, 59.7-72.2). HR for overall survival (OS) was 0.74 (95% CI 0.58 to 0.93; one-sided p=0.0043), and was 0.62 (95% CI 0.49 to 0.79; one-sided p<0.0001) after adjustment for crossover. Five-year OS rates were 31.2% (95% CI 24.7% to 37.9%) with camrelizumab plus chemotherapy versus 19.3% (95% CI 13.9% to 25.3%) with chemotherapy alone. Among the 33 patients who completed 2 years of camrelizumab, 5-year OS rate was 84.3% (95% CI 66.4% to 93.2%), and 5-year duration of response rate was 46.5% (95% CI 24.9% to 65.6%) in the 32 responders. No new safety signals were noted. CONCLUSIONS:Camrelizumab plus carboplatin and pemetrexed as first-line therapy continued to demonstrate long-term OS benefit over carboplatin and pemetrexed, with manageable toxicity. Patients who completed 2 years of camrelizumab had enduring response and impressive OS. Current 5-year updated analysis further supports camrelizumab plus carboplatin and pemetrexed as a standard-of-care for previously untreated advanced non-squamous NSCLC without EGFR/ALK alterations. TRIAL REGISTRATION NUMBER:NCT03134872.